TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia
Identifieur interne : 000D89 ( Main/Exploration ); précédent : 000D88; suivant : 000D90TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia
Auteurs : Teck Choon Tan [Singapour] ; Louise Wienholt [Australie] ; Stephen Adelstein [Australie]Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2016-10.
Abstract
Background: There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (MSA). We review the use of a line immunoassay‐based myositis panel incorporating both MSA and myositis‐associated autoantibodies (MAA) in a selected population of patients. Methods: A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses. Results: A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (IIM), 24 patients with suspected interstitial lung disease (ILD) and 12 patients with suspected systemic autoimmune disease (SAD). In the myositis group, there were 21 patients diagnosed with IIM and 18 patients diagnosed with IIM had a positive myositis panel. Of the 39 patients without IIM, nine of these patients had a positive myositis panel. In the ILD group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (ASS) and five patients with ILD. In the suspected SAD group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of IIM or ILD‐associated SAD, four patients with anti‐PL‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2. Conclusions: The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.
Url:
DOI: 10.1111/1756-185X.12792
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002A94
- to stream Istex, to step Curation: 002A94
- to stream Istex, to step Checkpoint: 000008
- to stream Main, to step Merge: 000D90
- to stream Main, to step Curation: 000D89
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><author><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name></author><author><name sortKey="Wienholt, Louise" sort="Wienholt, Louise" uniqKey="Wienholt L" first="Louise" last="Wienholt">Louise Wienholt</name></author><author><name sortKey="Adelstein, Stephen" sort="Adelstein, Stephen" uniqKey="Adelstein S" first="Stephen" last="Adelstein">Stephen Adelstein</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB068EA694A4870E19B5F8E3ACB15AD6B562FED9</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/1756-185X.12792</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002A94</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002A94</idno><idno type="wicri:Area/Istex/Curation">002A94</idno><idno type="wicri:Area/Istex/Checkpoint">000008</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000008</idno><idno type="wicri:doubleKey">1756-1841:2016:Tan T:test:performance:of</idno><idno type="wicri:Area/Main/Merge">000D90</idno><idno type="wicri:Area/Main/Curation">000D89</idno><idno type="wicri:Area/Main/Exploration">000D89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><author><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital</wicri:regionArea><wicri:noRegion>Tan Tock Seng Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Singapour</country></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Singapour</country></affiliation></author><author><name sortKey="Wienholt, Louise" sort="Wienholt, Louise" uniqKey="Wienholt L" first="Louise" last="Wienholt">Louise Wienholt</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Immunology, Royal Prince Alfred Hospital, New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Adelstein, Stephen" sort="Adelstein, Stephen" uniqKey="Adelstein S" first="Stephen" last="Adelstein">Stephen Adelstein</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney Medical School University of Sydney, New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="996">996</biblScope><biblScope unit="page" to="1001">1001</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-10">2016-10</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (MSA). We review the use of a line immunoassay‐based myositis panel incorporating both MSA and myositis‐associated autoantibodies (MAA) in a selected population of patients. Methods: A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses. Results: A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (IIM), 24 patients with suspected interstitial lung disease (ILD) and 12 patients with suspected systemic autoimmune disease (SAD). In the myositis group, there were 21 patients diagnosed with IIM and 18 patients diagnosed with IIM had a positive myositis panel. Of the 39 patients without IIM, nine of these patients had a positive myositis panel. In the ILD group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (ASS) and five patients with ILD. In the suspected SAD group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of IIM or ILD‐associated SAD, four patients with anti‐PL‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2. Conclusions: The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Singapour</li></country><region><li>Nouvelle-Galles du Sud</li></region><settlement><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Singapour"><noRegion><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name></noRegion><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Wienholt, Louise" sort="Wienholt, Louise" uniqKey="Wienholt L" first="Louise" last="Wienholt">Louise Wienholt</name></region><name sortKey="Adelstein, Stephen" sort="Adelstein, Stephen" uniqKey="Adelstein S" first="Stephen" last="Adelstein">Stephen Adelstein</name><name sortKey="Adelstein, Stephen" sort="Adelstein, Stephen" uniqKey="Adelstein S" first="Stephen" last="Adelstein">Stephen Adelstein</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BB068EA694A4870E19B5F8E3ACB15AD6B562FED9
|texte= TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia
}}
| This area was generated with Dilib version V0.6.33. |  |